Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN ® (dendritic cell‐based vaccine): a case report

APCEDEN® is an autologous monocyte‐derived dendritic cell‐based immunotherapy. A 58‐year‐old man with adenocarcinoma of oropharynx shows complete remission after receiving APCEDEN® in conjunction with Geftinib validated by reduction in size, whereas Gefitinib alone lead to disease progression.

• Publication year

  2017

• Venue

  Clinical Case Reports

• Publication date

  2017-09-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ccr3.1169PMID 29026574PMCID 5628247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients

  2017cited by this paper
• Treatment Outcomes of Rare Retromolar Trigone Squamous Cell Carcinoma Using Combined Modalities

  2017cited by this paper
• Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN ® (dendritic cell‐based vaccine): a case report

  2017cited by this paper
• The neutrophil-to-lymphocyte ratio: a narrative review

  2016cited by this paper
• Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

  2016cited by this paper
• Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

  2016cited by this paper
• Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7

  2016cited by this paper
• [Dendritic cell-based therapeutic cancer vaccines].

  2016cited by this paper
• Pseudoprogression and Immune-Related Response in Solid Tumors.

  2015cited by this paper
• Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

  2015cited by this paper
• Oral cavity and oropharyngeal squamous cell carcinoma—an update

  2015cited by this paper
• Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care.

  2014cited by this paper
• Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature

  2014cited by this paper
• Dendritic-cell-based therapeutic cancer vaccines.

  2013cited by this paper
• Evolution of end points for cancer immunotherapy trials.

  2012cited by this paper
• Basaloid squamous cell carcinoma of retromolar trigone: A case report with review of literature

  2011cited by this paper
• Immunotherapy of Lung Adenocarcinoma Patient with Peptide-Pulsed Dendritic Cells: a Case Report

  2011cited by this paper
• Oropharyngeal cancer: current understanding and management

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Manipulating dendritic cell biology for the active immunotherapy of cancer.

  2004cited by this paper
• Dendritic cell immunotherapy: mapping the way

  2004cited by this paper
• Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens

  2003cited by this paper
• Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

  2002cited by this paper
• Cancer of retromolar trigone: Long‐term radiation therapy outcome

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

  2000cited by this paper
• Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

  1999cited by this paper

• Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy

  2025cites this paper
• Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics.

  2023cites this paper
• Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy

  2019cites this paper
• Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN ® (dendritic cell‐based vaccine): a case report

  2017cites this paper